Baxter International Faces Class Action Lawsuit Over Pump Defects

Investors in Baxter International, Inc. have the opportunity to lead a class action lawsuit following significant allegations regarding the company’s Novum IQ Large Volume Pump. The lawsuit, initiated by the Electrical Workers Pension Fund, Local 103, I.B.E.W., claims that Baxter and its executives violated the Securities Exchange Act of 1934.

Purchasers of Baxter common stock between February 23, 2022, and July 30, 2025, are urged to act by December 15, 2025, to be considered for lead plaintiff status in this case, which is filed under the case number 25-cv-12672 in the Northern District of Illinois.

Robbins Geller Rudman & Dowd LLP announced the lawsuit on October 29, 2025, revealing that Baxter’s Novum IQ pump allegedly experienced systemic defects leading to serious malfunctions. These issues reportedly included underinfusion, overinfusion, and complete non-delivery of fluids, putting patients at risk of severe injury or even death.

Baxter was allegedly aware of multiple device malfunctions and the associated injuries, but its efforts to address these problems through customer alerts were insufficient, according to the lawsuit. The complaint alleges that Baxter’s design flaws persisted, resulting in ongoing harm to patients.

On July 31, 2025, Baxter announced a voluntary and temporary halt to shipments and installations of the Novum LVP, stating it could not guarantee a timeline for resuming these operations. This announcement led to a significant downturn, with Baxter’s stock price plummeting by more than 22%.

Details of the Allegations

The class action lawsuit outlines several key allegations against Baxter and its executives. It asserts that the defendants made false or misleading statements throughout the Class Period. Notably, it claims that Baxter’s attempts to rectify the issues were inadequate and that they failed to disclose the full extent of the malfunctions to investors and the public.

The lawsuit contends that these failures not only jeopardized patient safety but also significantly impacted the company’s financial standing. As a result, Baxter’s stockholders have suffered substantial losses, prompting the call for a lead plaintiff to represent their interests in the ongoing litigation.

The lead plaintiff process, as defined by the Private Securities Litigation Reform Act of 1995, allows any investor who purchased Baxter common stock during the Class Period to seek this role. The lead plaintiff will represent all class members and can select the legal firm to handle the case. Importantly, an investor’s potential recovery is not contingent on being the lead plaintiff.

The Role of Robbins Geller Rudman & Dowd LLP

Robbins Geller Rudman & Dowd LLP is recognized as one of the leading firms specializing in securities fraud and shareholder litigation. The firm has secured over $2.5 billion in recoveries for investors in 2024 alone, placing it at the forefront of securities class action recoveries globally.

With a team of approximately 200 attorneys across ten offices, Robbins Geller has a strong track record of achieving significant settlements for investors, including many of the largest recoveries in history.

For those affected by the alleged issues with Baxter’s Novum IQ pump, there is a pathway to seek justice through this class action. Interested investors can find more details and initiate their participation by visiting the firm’s official website or contacting the attorneys directly.

This lawsuit underscores the importance of accountability in the healthcare sector and the need for transparency regarding product safety and corporate disclosures. As the legal proceedings unfold, the implications for Baxter and its investors will become increasingly clear.